Ivacaftor (21) – Kalydeco®
Cystic fibrosis (CF), combination treatment with ivacaftor/tezacaftor/elexacaftor in patients ≥ 12 years (heterozygous for F508del and RF mutation)
Characteristics
| Start date | 01.06.2021 – Marketing authorisation: 26.04.2021 |
|---|---|
| Resolution | 19.11.2021 |
| INN | Ivacaftor |
| Brand name | Kalydeco® |
| Pharm. company | Vertex Pharmaceuticals (Germany) GmbH |
| G-BA Procedure ID | D-688 |
| ATC code | R07AX02 Other respiratory system products (R07AX) |
| ICD-10 codes (AIS) | E84.0Cystic fibrosis with pulmonary manifestations, E84.1Cystic fibrosis with intestinal manifestations, E84.80, E84.87, E84.88, E84.9Cystic fibrosis, unspecified |
| Alpha-ID codes (AIS) | I129376Neonatal hepatobiliary disease in cystic fibrosis, I130516Cystic fibrosis with other multiple manifestations, I18531Cystic fibrosis, I2487Cystic fibrosis with pulmonary manifestation, I2488Cystic fibrosis with intestinal manifestation, I32495Cystic fibrosis with manifestations in the lungs and digestive tract |
| ORPHAcodes (AIS) | 586Neonatal hepatobiliary disease in cystic fibrosis, 586Cystic fibrosis with other multiple manifestations, 586Cystic fibrosis, 586Cystic fibrosis with pulmonary manifestation, 586Cystic fibrosis with intestinal manifestation, 586Cystic fibrosis with manifestations in the lungs and digestive tract |
| DDD | 0.15 mg O |
| Therapeutic area | Metabolic diseases Cystic fibrosis (CF) Orphan (turnover limit) |
| Reason for procedure | New therapeutic indication – Orphan turnover exceeded |
| Specialty | Bundling |
| Therapeutic indication of the resolution |
|---|
|
Kalydeco tablets are indicated in a combination regimen with ivacaftor /tezacaftor /elexacaftor tablets for the treatment of adults and adolescents aged 12 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene |
| Subpopulation | Indication | Comparator |
|---|---|---|
| D) | Patients aged 12 years and older with cystic fibrosis (CF) who are heterozygous for the F508del mutation in the CFTR gene and carry a residual function mutation on the second allele. | Tezacaftor/Ivacaftor in combination with Ivacaftor |
Studies and Results
|
No. of studies
(best subpopulation) |
1 (VX18-445-10) |
|---|---|
|
Study design
(best subpopulation) |
H2H vs. ACT (off-label) |
|
Meta analysis
(best subpopulation) |
no |
- Clinical trials
- To assess the additional benefit of ivacaftor in combination with ivacaftor/tezacaftor/elaxacaftor in people aged 12 years and over with cystic fibrosis who are heterozygous for the F508del mutation in the CFTRgene and carry a residual-function mutation on the second allele, the pharmaceutical manufacturer submitted the Phase III, multicentre, randomised, double-blind, controlled trial VX18-445-104 (hereinafter ‘Study 104’) was submitted by the pharmaceutical company.
Individuals aged 12 years and over with cystic fibrosis who are heterozygous for the F508del mutation in the CFTR gene and carry a residual-function mutation on the second allele
- An additional benefit is not proven.
- Consequently, the pharmaceutical manufacturer did not submit any study for this patient population that would have been suitable for assessing the additional benefit of ivacaftor in combination with ivacaftor/tezacaftor/elexacaftor compared with the appropriate comparator therapy.
- Overall, additional benefit is not proven for people aged 12 years and over with cystic fibrosis who are heterozygous for the F508del mutation and carry a residual-function mutation on the second allele.
- Overall assessment
- On balance, additional benefit is not proven for people aged 12 years and over with cystic fibrosis who are heterozygous for the F508del mutation and carry a residual-function mutation on the second allele.
Courtesy translation only, please refer to the German original.
Associated procedures
<< List of all resolutions